Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 8:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–8 of 8 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Iron Overload, Sickle Cell Disease, Other Anemias
Interventions
Deferiprone, Deferoxamine
Drug
Lead sponsor
ApoPharma
Industry
Eligibility
2 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
8
States / cities
Oakland, California • Chicago, Illinois • New Orleans, Louisiana + 4 more
Terminated Phase 2 Interventional Results available

High-Dose Deferoxamine in Intracerebral Hemorrhage

NCT01662895
Conditions
Intracerebral Hemorrhage
Interventions
Deferoxamine, Normal saline
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
25
States / cities
Phoenix, Arizona • Palo Alto, California • San Francisco, California + 19 more
Conditions
Iron Overload, Thalassemia
Interventions
Combination Iron Chelation Therapy
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
7 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
New York, New York
Conditions
Cardiovascular Diseases, Heart Diseases, Beta-Thalassemia
Interventions
Deferoxamine, Deferiprone (L1)
Drug
Lead sponsor
Carelon Research
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
6
States / cities
Los Angeles, California • Oakland, California • Chicago, Illinois + 3 more
Completed Early Phase 1 Interventional Accepts healthy volunteers

Modulation of Cerebral Blood Flow Using Iron Chelators

NCT01365104
Conditions
Stroke, Problem of Aging
Interventions
desferrioxamine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Intracerebral Hemorrhage
Interventions
Deferoxamine Mesylate
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Lung Cancer, Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
Interventions
Zirconium Zr 89 crefmirlimab berdoxam, PET/CT Scan
Drug · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Chronic Cutaneous Ulcer, Sickle Cell Disease
Interventions
Deferoxamine Product, Placebo
Drug · Other
Lead sponsor
TauTona Group
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Birmingham, Alabama • Miami, Florida • Atlanta, Georgia + 1 more